computer anti-virus info

IBM (NYSE: IBM) announced today a radical new way for its small and medium business clients to adopt and manage their IT infrastructure. Small and medium business clients will now be able to purchase a complete, "all-in-one" system for their business on a per-user basis, enabling clients to grow technology resources at pace with business needs.

This scalable pricing model is being launched in conjunction with the new System i Express solution designed for 5 to 40 users as well as a second system optimized for the mid-market, both featuring IBM's leading POWER5+ processor.

"Every small and medium business has one thing in common -- the need to serve their customers and be ready for growth," said Mark Shearer, general manager for IBM System i. "Today, IBM is providing these clients simplified access to a complete system that is easy-to-manage, easy-to-secure an...

* Flu vaccine based on new technology within U.S. Government Preparedness Program

* Successful scale-up of PER.C6® to 20,000 liters

Lyon, France; Leiden, The Netherlands, September 26, 2006 - Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), initiated its first clinical study today with a new generation of seasonal influenza vaccine produced using the PER.C6® cell culture technology of Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX). This trial represents one of sanofi pasteur's initiatives to diversify flu vaccine manufacturing technologies.

The trial conducted in the United States is part of a contract awarded by the U.S. Department of Health and Human Services (HHS) to accelerate the development of a new cell culture-b...

Cenzic's Intelligent Analysis (CIA) research lab today named the top five most serious web application vulnerabilities for the months of May and June 2006. CIA specializes in the continuous research of application vulnerabilities and the development of remediation strategies to assist customers with their web application security needs in enterprise environments.

Under the auspice of CIA, Cenzic evaluates a wide range of newly discovered application vulnerabilities and prioritizes them based on their severity and potential to impact regulatory compliance, internal policy compliance, information privacy and financial losses. This information is released on a monthly or bi-monthly basis and can be used by enterprises as a first step in addressing the security of custom and commercial web applications.

The CIA team analyzed all web application security vulnerabilities discovered in May and June and named the following as the top five most serious vulnerabilities for this time per...

Fortinet -- the pioneer and leading provider of multi-threat security solutions -- today announced FortiClient Mobile, an integrated security software agent for Microsoft Windows Mobile and Symbian OS-enabled mobile smart phones and PDAs.

Extending the capabilities of Fortinet's FortiClient endpoint security software, FortiClient Mobile allows mobile operators and handset manufacturers to offer subscribers increased security. The software is the first mobile endpoint security solution on the market to integrate full antivirus, MMS/SMS anti-spam, personal firewall and address book protection and IPSec VPN capabilities to protect mobile subscribers against constantly evolving and sophisticated mobile threats.

FortiClient Mobile secures the growing number of smart phone subscribers that leverage standard operating systems such as Windows Mobile and Symbian. These operating systems provide powerful access to mobile enterprise applications, such as Microsoft Office Mobile, as well ...

Polydex Pharmaceuticals Limited (NASDAQ: POLXF) has announced the results for its fiscal year ending January 31, 2006. All figures are reported in US dollars. Sales of the Company for the year ending January 31, 2006 amounted to $5,265,209 and the Company incurred a net loss of $1,489,053 for the year. This net loss is a result of the decrease in sales and gross margin at Dextran, and can be primarily attributed to the continued increase in value of the Canadian dollar relative to the U.S. dollar. Dextran Products' sales decreased by 4% during fiscal year ended January 31, 2006, but since most of the Company's sales are denominated in U.S. dollars, while its costs are primarily denominated in Canadian dollars, the rise in value of the Canadian dollar also resulted in increased cost of sales. In addition, the gross margins were affected by other factors, including supplier price increases, increas...

Key figures

Nine months to September 30

Third quarter

Excluding charges related to Chiron acquisition, Q3 Group operating income rises 24% and net income up 22%

(1) Tekturna replaces Rasilez as the proposed global brand name for aliskiren

All product names appearing in italics are trademarks of Novartis Group Companies

Basel, October 19, 2006 -- Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis, said, "I am pleased that all of our divisions delivered strong results in the first nine months of the year. Pharmaceuticals delivered double-digit growth in our Cardiovascular, Oncology and Neuroscience franchises further strengthening their market positions. Our Vaccines and Diagnostics business is progressing well, already having made the industry's first shipments of injectable influenza vaccines to the US. Thanks to our commitment to innovation, we have a full pipeline and have completed major submissions in the US and ...